Skip to main content
. 2021 May 26;12:681223. doi: 10.3389/fphar.2021.681223

FIGURE 6.

FIGURE 6

Lidocaine/miR-382-5p axis reduces the proliferation of ovarian and breast cancer cells by targeting SLC7A11 in vitro. (A–D) SKOV-3 and T47D cells were co-treated with lidocaine (3 mM) and miR-382-5p inhibitor or SLC7A11 reconstitution vectors. (A,B) The cell viability was detected by MTT assays. (C,D) The apoptosis was analyzed by flow cytometry. mean ± SD, **p < 0.01. The experiments were performed independently three times.